期刊文献+

精准医学对慢性病防控的作用及发展策略 被引量:4

The role and development strategy of precision medicine in prevention and control of chronic diseases
下载PDF
导出
摘要 建立在生物大数据分析、基因测序技术等基础上的精准医学的发展,为慢性病防控提供了新的思路和方向。本文对精准医学的内涵、对慢性病防控的作用及其价值评估等进行概述,并提出精准医学在慢性病防控领域的发展策略,以期为我国慢性病防控模式的创新发展提供参考。 The development of precision medicine based on the biological big data analysis, gene sequencing technology and others, have provided new ideas and direction for the prevention and control of chronic diseases. This paper summarized the connotation of precision medicine, its effect on the prevention and control of chronic diseases and its value assessment, and put forward the development strategy of precision medicine in chronic disease prevention and control field, in order to provide reference for the innovative development of China's chronic disease prevention and control pattern.
作者 吴伟旋 向前 许军 刘冬 WU Wei-xuan XIANG Qian XU Jun LIU Dong(Nanfang Hospital of Southern Medical University, Guangzhou Guangdong 510515,China Health economics association of Guangdong province, Guangzhou Guangzhou 510515,China)
出处 《卫生经济研究》 北大核心 2017年第7期44-47,共4页
基金 广东省医学科学技术研究基金(A2015598) 广东省医学科学技术研究基金(C2016067) 2016年广州市公共卫生服务体系建设研究基地课题
关键词 精准医学 慢性病防控 价值评估 发展策略 Precision medicine Chronic disease prevention and control Value assessment Development strategy
  • 相关文献

参考文献7

二级参考文献117

  • 1O'Brien SG,Guilhot F,Larson RA,et al.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med,2003,348:994-1004.
  • 2Kantarjian HM,O'Brien S,Cortes J,et al.Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase:comparison with historic data.Cancer,2003,98:2636-2642.
  • 3Simonsson B.Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM):update from the IRIS study.Blood,2005,106:abstract # 166.
  • 4Goldman JM,Hughes T,Radich J,et al.Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IBIS study.Blood,2005,106:abstract #163.
  • 5Kantarjian HM,Cortes JE,O'Brien S,et al.Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.Blood,2004,104:1979-1988.
  • 6Talpaz M,Silver RT,Druker BJ,et al.Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia:results of a phase 2 study.Blood,2002,99:1928-1937.
  • 7Kantarjian HM,Cortes J,O'Brien S,et al.Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.Blood,2002,99:3547-3553.
  • 8Dagher R,Cohen M,Williams G,et al.Approval summary:imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.Clin Cancer Res,2002,8:3034-3038.
  • 9Bartolovic K,Balabanov S,Hartmann U,et al.Inhibitory effect of imatinib on normal progenitor cells in vitro.Blood,2004,103:523-529.
  • 10Sneed TB,Kantarjian HM,Talpaz M,et al.The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.Cancer,2004,100:116-121.

共引文献96

同被引文献40

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部